Jeffrey Blitstein, MD
Urology · Berkeley Heights, NJNPI 1538367396
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 16 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Myriad Genetic Laboratories, Inc. accounts for 81.6% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2023 at $298 and has fallen 92.1% since, to $23 in 2025. That places this record below the midpoint for urology clinicians in NJ, where the typical reported total is $2,095.
Across 16 payments — averaging $29.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Myriad Genetic Laboratories, Inc.$380
- Boston Scientific$62
- C. R. Bard, Inc. & Subsidiaries$23
What the payments were for
- Food & beverage$465100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Myriad Genetic Laboratories, Inc. | 12 | $380 |
| Boston Scientific | 3 | $62 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $23 |
How this compares
$465 in reported general payments places this provider in the 20th percentile of 401 urology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 402 | $316,898 |
| GemtesaVibegron | 67 | $68,518 |
| Tamsulosin Hcl | 1,676 | $30,578 |
| Silodosin | 282 | $29,710 |
| Finasteride | 1,093 | $16,265 |
| Testosterone | 88 | $15,868 |
| Potassium Citrate ErPotassium Citrate | 124 | $15,188 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 589 | $14,121 |
| Mirabegron ErMirabegron | 20 | $11,302 |
| Methenamine Hippurate | 69 | $9,206 |
| Oxybutynin Chloride ErOxybutynin Chloride | 163 | $4,651 |
| Dutasteride | 102 | $4,164 |
| Tadalafil | 86 | $2,964 |
| Trospium Chloride ErTrospium Chloride | 16 | $2,603 |
| Solifenacin Succinate | 59 | $2,298 |
Paid to pharmacies, not to this prescriber.
Other urology in Berkeley Heights
- Michael StifelmanHackensack$1.4M
- Gordon BrownCherry Hill$1.3M
- Thomas MuellerLinwood$1.1M
- David SussmanLinwood$802K
- Michael IngberDenville$530K
- Ravi MunverHackensack$529K
- Grannum SantBridgewater$487K
- Mutahar AhmedMaywood$414K
- Kevin GioiaRumson$143K
- Robert SimonCliffside Park$108K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.